Advanced renal cell carcinoma treatment market seen reaching $12.52 billion by 2030

The market for advanced renal cell carcinoma treatment is projected to grow from $8.73 billion in 2025 to $12.52 billion by 2030, driven by targeted therapies, immunotherapy research and personalized medicine. North America held the largest regional share in 2025, while the report flags growing demand tied to genetic disorders linked to renal cell carcinoma.

Why it matters: - Advanced renal cell carcinoma is a serious cancer that has spread beyond the kidney, and treatment demand is rising as diagnosis and therapy options expand. - The market outlook signals more spending on targeted drugs, immunotherapy and combination approaches that could shape care for patients with advanced disease.

What happened: - The Business Research Company released its Renal Cell Carcinoma Treatment Global Market Report 2026 covering market size, trends and forecasts for 2026-2035. - The report says the advanced renal cell carcinoma treatment market is projected to rise from $8.73 billion in 2025 to $9.4 billion in 2026. - The same report forecasts the market will reach $12.52 billion by 2030. - North America held the largest share of the market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The report links recent market growth to limited treatment options for advanced RCC, heavy use of traditional chemotherapy, rising case counts, expanding oncology services in hospitals and more clinical research activity. - The forecast through 2030 is tied to new biologic therapies, targeted inhibitors, more funding for immunotherapy research, personalized medicine strategies, broader use of minimally invasive techniques and growth in cancer vaccine therapies. - Expected trend lines include wider use of targeted RCC treatments, more immune checkpoint inhibitors, more combination therapies, more individualized treatment plans and advances in peptide- and DNA-based cancer vaccines. - Advanced RCC treatment includes targeted therapies, immunotherapy and, in some cases, radiation therapy to help control tumor growth or symptoms. - The report says genetic disorders linked to renal cell carcinoma are a major demand driver because treatments are becoming more personalized to a patient’s molecular profile. - The report cites Gene People, a UK charity, saying about 1 in 25 children in the UK are affected by genetic conditions, more than 2.4 million people in the country live with such disorders, and around 30,000 newborns and children are diagnosed each year. - The report says North America leads because of established healthcare infrastructure, heavy oncology research investment and broad adoption of innovative therapies. - The 2026 edition includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis and updated graphics and tables. - The report offers a free sample and the full market report.

Between the lines: - The forecast suggests advanced RCC is moving from a chemotherapy-heavy market toward more precision-based care. - North America’s lead points to faster uptake of newer therapies where research funding, specialist care and regulatory access are already stronger. - The genetic-disorder angle suggests future growth may come not only from more patients, but from more tailored treatment decisions.

What's next: - The market is expected to keep expanding through 2030 as biologics, immunotherapy and vaccine research mature. - Combination regimens and individualized treatment planning are likely to remain the main competitive themes. - The report’s forecast implies continued demand for oncology infrastructure, clinical research and advanced diagnostics.

The bottom line: - Advanced renal cell carcinoma treatment is entering a growth phase powered by precision medicine, immunotherapy and a broader pipeline of targeted options.